Anesthesia Several synthetic neurosteroids have been used as
sedatives for the purpose of
general anaesthesia for carrying out surgical procedures. The best known of these are
alphaxolone,
alphadolone,
hydroxydione, and
minaxolone. The first of these to be introduced was hydroxydione, which is the esterified 21-hydroxy derivative of 5β-pregnanedione. Hydroxydione proved to be a useful anaesthetic drug with a good safety profile, but was painful and irritating when injected probably due to poor water solubility. This led to the development of newer neuroactive steroids. The next drug from this family to be marketed was a mixture of alphaxolone and alphadolone, known as
Althesin. This was withdrawn from human use due to rare but serious toxic reactions, but is still used in
veterinary medicine. The next neurosteroid anaesthetic introduced into human medicine was the newer drug minaxolone, which is around three times more potent than althesin and retains the favourable safety profile, without the toxicity problems seen with althesin. However this drug was also ultimately withdrawn, not because of problems in clinical use, but because animal studies suggested potential carcinogenicity and since alternative agents were available it was felt that the possible risk outweighed the benefit of keeping the drug on the market.
Ganaxolone The neurosteroid
ganaxolone, an analog of the progesterone metabolite allopregnanolone, has been extensively investigated in animal models and is currently in clinical trials for the treatment of
epilepsy. Neurosteroids, including ganaxolone have a broad spectrum of activity in animal models. They may have advantages over other GABAA receptor modulators, notably benzodiazepines, in that tolerance does not appear to occur with extended use. A randomized, placebo controlled, 10-week phase 2 clinical trial of orally administered ganaxolone in adults with partial onset seizure demonstrated that the treatment is safe, well tolerated and efficacious.
Micronized progesterone, which behaves reliably as a
prodrug to allopregnanolone, has been suggested as a treatment for catamenial epilepsy in the same manner.
Allopregnanolone Allopregnanolone (SAGE-547) is under development as an
intravenous therapy for the treatment of
super-refractory status epilepticus,
postpartum depression, and
essential tremor.
Other applications 4,16-Androstadien-3β-ol (PH94B, Aloradine) is a synthetic pheromone, or
pherine, neurosteroid which is under investigation for the treatment of
anxiety disorders in women.
3β-Methoxypregnenolone (MAP-4343), or pregnenolone 3β-methyl ether, is a synthetic neuroactive steroid and pregnenolone derivative that interacts with
microtubule-associated protein 2 (MAP2) in a similar manner to pregnenolone and is under development for potential clinical use for indications such as the treatment of
brain and
spinal cord injury and
depressive disorders. ==Role in antidepressant action==